Literature DB >> 22315487

Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia.

Bruno C Medeiros1, Megan Othus, Elihu H Estey, Min Fang, Frederick R Appelbaum.   

Abstract

BACKGROUND: Obesity increases the risk of treatment-related complications and reduces survival in children with acute myeloid leukemia. Little is known about the impact of obesity on the outcome of adult patients with acute myeloid leukemia. DESIGN AND METHODS: We compared the baseline characteristics and effect on treatment and survival in 1,974 previously untreated adult patients with acute myeloid leukemia undergoing treatment, according to international classification of body-mass index.
RESULTS: The median body-mass index was 26.7 (15.5-61) and 63% of patients were overweight/obese. After adjustment for other confounders, such as age, gender, performance status, karyotype, white blood cell, platelet and peripheral blast counts, obese patients had better complete remission rates (P=0.0046), lower rates of resistant disease (P=0.038) but similar rates of survival and severe adverse events.
CONCLUSIONS: In the treatment of acute myeloid leukemia in adults, obesity was associated with increased response rates and no apparent increase in toxicity. Obesity should not, therefore, be a criterion for excluding patients from aggressive therapy.

Entities:  

Mesh:

Year:  2012        PMID: 22315487      PMCID: PMC3436242          DOI: 10.3324/haematol.2011.056390

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  17 in total

1.  Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia.

Authors:  E Estey; P Thall; H Kantarjian; S Pierce; S Kornblau; M Keating
Journal:  Leukemia       Date:  1997-10       Impact factor: 11.528

2.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2000

3.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

4.  Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version.

Authors:  Cynthia L Ogden; Robert J Kuczmarski; Katherine M Flegal; Zuguo Mei; Shumei Guo; Rong Wei; Laurence M Grummer-Strawn; Lester R Curtin; Alex F Roche; Clifford L Johnson
Journal:  Pediatrics       Date:  2002-01       Impact factor: 7.124

5.  Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.

Authors:  G L Rosner; J B Hargis; D R Hollis; D R Budman; R B Weiss; I C Henderson; R L Schilsky
Journal:  J Clin Oncol       Date:  1996-11       Impact factor: 44.544

Review 6.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

7.  Mortality in overweight and underweight children with acute myeloid leukemia.

Authors:  Beverly J Lange; Robert B Gerbing; James Feusner; Jeffrey Skolnik; Nancy Sacks; Franklin O Smith; Todd A Alonzo
Journal:  JAMA       Date:  2005-01-12       Impact factor: 56.272

Review 8.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies.

Authors:  Andrew G Renehan; Margaret Tyson; Matthias Egger; Richard F Heller; Marcel Zwahlen
Journal:  Lancet       Date:  2008-02-16       Impact factor: 79.321

9.  Future of cancer incidence in the United States: burdens upon an aging, changing nation.

Authors:  Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2009-04-29       Impact factor: 44.544

10.  Doxorubicin clearance in the obese.

Authors:  K A Rodvold; D A Rushing; D A Tewksbury
Journal:  J Clin Oncol       Date:  1988-08       Impact factor: 44.544

View more
  20 in total

1.  Effect of body mass index on the outcome of children with acute myeloid leukemia.

Authors:  Hiroto Inaba; Harriet C Surprise; Stanley Pounds; Xueyuan Cao; Scott C Howard; Karen Ringwald-Smith; Jassada Buaboonnam; Gary Dahl; W Paul Bowman; Jeffrey W Taub; Dario Campana; Ching-Hon Pui; Raul C Ribeiro; Jeffrey E Rubnitz
Journal:  Cancer       Date:  2012-05-30       Impact factor: 6.860

2.  Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004.

Authors:  Ditte J A Løhmann; Jonas Abrahamsson; Shau-Yin Ha; Ólafur G Jónsson; Minna Koskenvuo; Birgitte Lausen; Josefine Palle; Bernward Zeller; Henrik Hasle
Journal:  Haematologica       Date:  2016-07-28       Impact factor: 9.941

3.  Does being overweight contribute to longer survival rates in myelodysplastic syndrome?

Authors:  Eric Solary; Michaela Fontenay
Journal:  Haematologica       Date:  2018-04       Impact factor: 9.941

4.  The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).

Authors:  Vicki A Morrison; Linda McCall; Hyman B Muss; Aminah Jatoi; Harvey J Cohen; Constance T Cirrincione; Jennifer A Ligibel; Jacqueline M Lafky; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2017-12-08       Impact factor: 3.599

5.  Body mass index is a prognostic factor in adult patients with acute myeloid leukemia.

Authors:  Taiki Ando; Etsuko Yamazaki; Eriko Ogusa; Yoshimi Ishii; Wataru Yamamoto; Kenji Motohashi; Takayoshi Tachibana; Maki Hagihara; Kenji Matsumoto; Masatsugu Tanaka; Chizuko Hashimoto; Hideyuki Koharazawa; Katsumichi Fujimaki; Jun Taguchi; Hiroyuki Fujita; Heiwa Kanamori; Shin Fujisawa; Hideaki Nakajima
Journal:  Int J Hematol       Date:  2017-01-21       Impact factor: 2.490

6.  Chemotherapy dose in obese AML patients: to cap or not to cap?

Authors:  Mary-Elizabeth M Percival; Bruno C Medeiros
Journal:  Leuk Res       Date:  2014-11-07       Impact factor: 3.156

7.  Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia.

Authors:  Haiwu Cao; Xiaohong Zhao; Shiyun Lu; Zhi Wang
Journal:  Exp Ther Med       Date:  2018-04-30       Impact factor: 2.447

8.  Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia.

Authors:  Andrew M Brunner; Hossein Sadrzadeh; Yang Feng; Benjamin J Drapkin; Karen K Ballen; Eyal C Attar; Philip C Amrein; Steven L McAfee; Yi-Bin Chen; Donna S Neuberg; Amir T Fathi
Journal:  Am J Hematol       Date:  2013-05-30       Impact factor: 10.047

9.  Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials.

Authors:  Jorge J Castillo; Flora Mulkey; Susan Geyer; Jonathan E Kolitz; William Blum; Bayard L Powell; Stephen L George; Richard A Larson; Richard M Stone
Journal:  Am J Hematol       Date:  2015-11-26       Impact factor: 10.047

10.  Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy.

Authors:  Etan Orgel; Nicole M Mueske; Richard Sposto; Vicente Gilsanz; David R Freyer; Steven D Mittelman
Journal:  Leuk Lymphoma       Date:  2016-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.